Trial Profile

A Phase 1/2 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of VIR-2218 Alone or in Combination With Pegylated Interferon Alpha-2a

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 26 Sep 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Elebsiran (Primary) ; Peginterferon alfa (Primary)
Indications Hepatitis B
Focus Adverse reactions
Sponsors Vir Biotechnology

Most Recent Events

19 Sep 2024 Status changed from active, no longer recruiting to completed.
01 May 2024 Planned End Date changed from 1 Apr 2024 to 1 Nov 2024.
14 Nov 2023 Results assessing the potential effect of region on VIR-2218 pharmacokinetics (PK) via cross-study comparison (VIR-2218-1001 and VIR-2218-1005) presented at The Liver Meeting 2023: 74th Annual Meeting of the American Association for the Study of Liver Diseases

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com